Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

Delayed Quote. Delayed  - 02/11 03:59:59 pm
67.26 USD   +0.36%
01/28 BIOMARIN TO HOS : 30pm ET
01/19 NASDAQ 100 MOVE : Bmrn, viab
01/15 BIOMARIN PHARMA : FDA Issues Complete Response Letter for KyndrisaTM..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/05/2016 02/08/2016 02/09/2016 02/10/2016 02/11/2016 Date
68.41(c) 64.74(c) 65.11(c) 67.02(c) 67.26(c) Last
2 239 141 1 839 042 2 478 184 1 861 439 1 641 820 Volume
-3.85% -5.36% +0.57% +2.93% +0.36% Change
More quotes
Financials ($)
Sales 2015 888 M
EBIT 2015 -76,1 M
Net income 2015 -96,0 M
Finance 2015 408 M
Yield 2015 -
Sales 2016 1 158 M
EBIT 2016 -281 M
Net income 2016 -306 M
Finance 2016 113 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
EV / Sales 2015 11,8x
EV / Sales 2016 9,27x
Capitalization 10 846 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.It operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's products include... 
Sector
Pharmaceuticals
Calendar
02/25Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
01/28 BIOMARIN TO HOST FOURTH QUARTER AND : 30pm ET
01/19 NASDAQ 100 MOVERS : Bmrn, viab
01/15 BIOMARIN PHARMACEUTICAL : FDA Issues Complete Response Letter for KyndrisaTM for..
01/15DJBIOMARIN PHARMACEUTICAL : Sarepta Shares Plunge as FDA Raises Doubts About Drug
01/14 BIOMARIN PHARMACEUTICAL : FDA: Duchenne muscular dystrophy drug not ready for ap..
01/14 NASDAQ 100 MOVERS : Bmrn, ntap
01/14 BIOMARIN PHARMACEUTICAL : FDA Issues Complete Response Letter for KyndrisaTM for..
01/14 FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dys..
More news
Sector news : Generic Pharmaceuticals
04:28aDJGLAXOSMITHKLINE : UK Regulator Fines GSK Over Generic Drug Delay - Update
03:20a UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals
02:48aDJGLAXOSMITHKLINE : Fined GBP37.61 Million for Paying off Competitors
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
02/11 The Touchstone Sands Capital Institutional Growth Fund Is Feeling The Pain
02/04 Recent Setbacks Have Duchenne Investors On Edge
01/26 Akashi suspends enrollment in Duchenne muscular dystrophy study
01/25 Catabasis Pharma's DMD candidate successful in Phase 1
01/22 HEALTHCARE RATINGS ROUNDUP : Credit Suisse


Comments 
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions